The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro

Head and Face Medicine

Volumn 6, Issue 1, 2010, Pages

  Koch, Felix P ^a   Yekta, Sareh S ^b   Merkel, Christina ^a   Ziebart, Thomas ^a   Smeets, Ralf ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; ECM1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; SCLEROPROTEIN; ZOLEDRONIC ACID;

ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; IN VITRO STUDY; OSTEOBLAST; PROTO ONCOGENE;

BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; COLLAGEN TYPE I; DIPHOSPHONATES; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GENES, BCL-1; HUMANS; IMIDAZOLES; OSTEOBLASTS;

EID: 77954344518     PISSN: None     EISSN: 1746160X     Source Type: Journal    
DOI: 10.1186/1746-160X-6-12     Document Type: Article

References (31)

1. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106. 10.1016/S8756-3282(99)00116-7, 10423031.
2. Glatt M, Pataki A, Evans GP, Hornby SB, Green JR. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 2004, 15:707-715. 10.1007/s00198-004-1588-3, 15024556.
3. Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 2003, 72:519-527. 10.1007/s00223-002-2015-4, 12574877.
4. Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997, 249:458-468. 10.1002/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N, 9415453.
5. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92:2577-2586. 10.1172/JCI116872, 288453, 8254015.
6. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141:4793-4796. 10.1210/en.141.12.4793, 11108295.
7. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999, 96:133-138. 10.1073/pnas.96.1.133, 15105, 9874784.
8. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
9. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589. 10.1359/jbmr.1998.13.4.581, 9556058.
10. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ. JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998). J Bone Miner Res 2005, 20:1265-1274. 10.1359/jbmr.2005.20.7.1265, 16050006.
11. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L, 10898340.
12. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33:805-811. 10.1016/j.bone.2003.07.007, 14623056.
13. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002, 25:539-546.
14. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25:4105-4115. 10.1016/j.biomaterials.2003.11.024, 15046901.
15. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005, 26:6941-6949. 10.1016/j.biomaterials.2005.04.059, 16009417.
16. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587. 10.1200/JCO.2005.02.8670, 16314620.
17. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575. 10.1016/j.joms.2005.07.010, 16243172.
18. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009, 115:1631-1637. 10.1002/cncr.24119, 19156913.
19. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008, 54:1066-1072. 10.1016/j.eururo.2008.06.070, 18602738.
20. Walter C, Grötz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007, 15:197-202. 10.1007/s00520-006-0120-z, 16941133.
21. Abu-Id MH, Açil Y, Gottschalk J, Kreusch T. [Bisphosphonate-associated osteonecrosis of the jaw]. Mund Kiefer Gesichtschir 2006, 10:73-81. 10.1007/s10006-005-0670-0, 16456688.
22. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534. 10.1016/j.joms.2004.02.004, 15122554.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034. 10.1186/gb-2002-3-7-research0034, 126239, 12184808.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:45.
25. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199. 10.1056/NEJMoa030897, 15028823.
26. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996, 18:141-150. 10.1016/8756-3282(95)00436-X, 8833208.
27. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333:1437-1443. 10.1056/NEJM199511303332201, 7477143.
28. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998, 83:396-402. 10.1210/jc.83.2.396, 9467547.
29. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
30. Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem 1998, 68:186-194. 10.1002/(SICI)1097-4644(19980201)68:2<186::AID-JCB5>3.0.CO;2-R, 9443074.
31. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480. 10.1172/JCI119668, 508326, 9294113.